Healthcare Executive Faints During Weight Loss Drug Announcement
Gordon Findlay, a healthcare executive at Novo Nordisk, fainted Thursday in the Oval Office while the White House announced a new deal on weight loss drugs.
Incident Details
The event focused on GLP-1 weight loss medications was interrupted when Findlay lost consciousness during Eli Lilly CEO David Ricks' speech. The press was quickly escorted out, and medical assistance was provided.
“During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted,” said White House Press Secretary Karoline Leavitt. “The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Official Response
- President Donald Trump and Dr. Mehmet Oz immediately shifted focus to Findlay.
- Deputy Press Secretary Kush Desai confirmed Dr. Kennedy left to get medical help during the incident.
- The press conference resumed by 1:29 p.m. after the situation stabilized.
Context of Announcement
The announcement revealed a deal between the government, Eli Lilly, and Novo Nordisk to offer some obesity drugs in the U.S. at around $150 for a month's supply, aiming to improve access and affordability.
Summary: During the White House announcement on affordable weight loss drugs, Novo Nordisk’s executive Gordon Findlay fainted, prompting a brief pause in the event and immediate medical response.